or Try an Advanced Search...

    Transplantation Stocks List

    Symbol Grade Name % Change
    TMDX B TransMedics Group, Inc. 6.50
    PLUR B Pluri Inc. -2.71
    JAZZ C Jazz Pharmaceuticals plc 3.75
    MESO D Mesoblast Limited -7.09
    TCRX D TScan Therapeutics, Inc. -4.34
    JSPR D Jasper Therapeutics, Inc -6.22
    CVM D Cel-Sci Corporation 3.54
    OPT F Opthea Limited -1.94
    INAB F IN8bio, Inc. 1.20
    ATNM F Actinium Pharmaceuticals, Inc. -4.34
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Biotechnology Cancer Medicine Stem Cell Life Sciences Host Disease Immunology Biopharmaceutical Bone Bone Marrow Clinical Medicine Graft Versus Host Disease Hematopoietic Stem Cell Immune System Immunotherapy Monoclonal Antibody Organ Transplant Organ Transplantation Rheumatoid Arthritis Solid Tumors

    Related ETFs - A few ETFs which own one or more of the above listed Transplantation stocks.

    Symbol Grade Name Weight
    SURI B Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 6.31
    IWC B iShares Microcap ETF 5.0
    IWO B iShares Russell 2000 Growth ETF 4.0
    IWM B iShares Russell 2000 ETF 4.0
    PTH B Invesco DWA Healthcare Momentum ETF 3.84
    View all Transplantation ETFs...
    Compare ETFs
    Compare IWC to PTH Compare IWO to PTH Compare SURI to IWO

        Transplantation Stocks Recent News

        Date Stock Title
        Aug 1 TMDX Why TransMedics Group Stock Is Soaring Today
        Aug 1 ATNM Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
        Aug 1 TMDX TransMedics Group, Inc. (TMDX) Q2 2024 Earnings Call Transcript
        Jul 31 JAZZ Jazz Pharmaceuticals plc 2024 Q2 - Results - Earnings Call Presentation
        Jul 31 JAZZ Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript
        Jul 31 JAZZ Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
        Jul 31 TMDX TransMedics (TMDX) Q2 Earnings and Revenues Top Estimates
        Jul 31 TMDX TransMedics: Q2 Earnings Snapshot
        Jul 31 TMDX TransMedics Group GAAP EPS of $0.35 beats by $0.14, revenue of $114.3M beats by $15.34M
        Jul 31 JAZZ Jazz: Q2 Earnings Snapshot
        Jul 31 JAZZ Jazz Pharmaceuticals beats Q2 estimates, narrows FY revenue guidance
        Jul 31 JAZZ Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
        Jul 31 TMDX TransMedics Reports Second Quarter 2024 Financial Results
        Jul 31 MESO Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
        Jul 30 TMDX TransMedics Group Q2 2024 Earnings Preview
        Jul 30 JAZZ Jazz Pharmaceuticals Q2 2024 Earnings Preview
        Jul 29 TMDX TransMedics to Present at the Canaccord Genuity 44th Annual Growth Conference
        Jul 29 CVM CEL-SCI Announces Closing of $10.8 Million Offering
        Jul 29 MESO Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
        Jul 29 TMDX Wall Street's Insights Into Key Metrics Ahead of TransMedics (TMDX) Q2 Earnings
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Biotechnology Cancer Medicine Stem Cell Life Sciences Host Disease Immunology Biopharmaceutical Bone Bone Marrow Clinical Medicine Graft Versus Host Disease Hematopoietic Stem Cell Immune System Immunotherapy Monoclonal Antibody Organ Transplant Organ Transplantation Rheumatoid Arthritis Solid Tumors
        Transplantation

        Browse All Tags